Anker SD, Butler J, Filippatos G, et al. - This study was intended to present the baseline characteristics of the EMPEROR‐Preserved cohort and correlates it with patients enrolled in prior heart failure with preserved ejection fraction (HFpEF) trials. Researchers designed EMPEROR‐Preserved, which was a phase III randomized, international, double‐blind, parallel‐group, placebo‐controlled trial including 5,988 symptomatic HFpEF patients (left ventricular ejection fraction [LVEF] > 40%) with and without type 2 diabetes mellitus. This study’s findings revealed that the EMPEROR‐Preserved cohort has a somewhat higher burden of co‐morbidities, lower LVEF, higher median NT‐proBNP, and greater use of mineralocorticoid receptor antagonists at baseline when compared with prior trials in HFpEF. Outcomes of the EMPEROR‐Preserved trial will be available in 2021.